Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of sevasemten in adults and adolescents with Becker muscular dystrophy
MOH_2025-11-26_015498Phase 2Not yet recruiting
- Sponsor
- Edgewise Therapeutics
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sevasemten in Becker muscular dystrophy (BMD), sponsored by Edgewise Therapeutics. Primary endpoint: Long-term safety and tolerability of sevasemten. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
sevasemten
03
Conditions
Becker muscular dystrophy (BMD)
Beyond the preview
Go deeper on MOH_2025-11-26_015498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-11-26_015498.